Evaluation of OneTouch Verio<sup>®</sup>, a new blood glucose self-monitoring system for patients with diabetes

Littmann, K.; Petersen, Eva Rabing Brix; Pussinen, Christel; Danielson, Kristin; Djurisic, Snezana; Eilertsen, Heidi; Garabet, Lamya; Greibe, Eva; Lauritzen, Trine; Olsen, Dorte Aalund; Othman, Suher; Palimaru, Irina; Westerlund, Johanna

doi:10.3109/00365513.2013.773064

Cited by 11 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certainly, enhancement in treatment satisfaction may play a critical role in increasing patient self-efficacy and commitment to therapy, thereby supporting in reaching long-term stable glycemic control, in addition to the minimization of the risk of diabetic complications [18]. More recently, diabetes technology has extended, and studies reported that technological improvements in glucometers are enhanced diabetes management and patient satisfaction [19,[23][24][25]. In this present study, we explored whether the smartLIGHT™ based BGM can impact the clinical characteristics and GMS in T2D patients over a period of time.…”

Section: Discussionmentioning

confidence: 99%

“…It is well demonstrated that diabetes technology has expanded. Studies reported that technological improvements in glucometers, including SmartLIGHT™ glucometers, improve diabetes management and patient satisfaction due to on-screen glucose range information using a color range indicator [6,19,[23][24][25]27]. Studies also reported that a blood glucose meter that provides automatic on-screen glucose range information using a color range indicator significantly improved the ability of patients having T2D to classify blood glucose readings into low range, in the range, or high glycemic range [6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Hayek¹,

Robert²,

Dawish³

2020

Cureus

View full text Add to dashboard Cite

Introduction Self-monitoring of blood glucose (SMBG) plays an important role in diabetes management. The Contour ® Next One glucometer is a recent glucometer that delivers blood glucose results by an immediate color indicator to aware users when blood glucose is at a critical high or low. The main purpose of the study was to assess the impact of an application of a blood glucose meter (BGM) having a color range indicator on clinical characteristics and glucose monitoring satisfaction (GMS) among patients having type 2 diabetes (T2D). Methods A total of 85 (male 42 and female 43) patients with T2D were switched to a BGM having smartLIGHT™ target range indicator (blood glucose meters featuring color range indicator) using Contour ® Next One glucometer. Demographic data, as well as glycemic control, were collected at baseline and 12 weeks. At the time of the baseline and 12 weeks of the study, a trained interviewer gave the GMS survey questionnaire to every patient in order to collect the glucose monitoring satisfaction. In addition to GMS, a patient's perceptions of smartLIGHT™ feature satisfaction survey responses were also collected from the patients at the end of the study (12 weeks). Results Compared to baseline, a significant improvement was observed in the subdomains of glucose monitoring satisfaction survey (GMSS) score on openness (p=0.0001), emotional burden (p=0.0001), behavioral burden (p=0.0001), and trust (p=0.0001) at the end of the study. Overall, the total GMS score at baseline was 2.61 ± 0.51, which improved up to 3.16 ± 0.63 (p=0.0001) during the period of 12 weeks. The patient satisfaction with smartLIGHT™ survey outcomes exposed evidence of satisfaction among the study population at the end of the study. There were statistically insignificant reductions observed in glycosylated hemoglobin (HbA1c) (p=0.063) and the frequency of hypoglycemia (p=0.057) at the end of the study. Conclusions The study demonstrates a significant improvement in the subdomains of GMSS-openness, emotional burden, behavioral burden, and trust-at 12 weeks than at the baseline, with the increased total GMSS score. Similarly, high satisfaction with the color-based smartLIGHT™ feature was also observed at the end of the study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Hayek¹,

Robert²,

Dawish³

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…In addition, each woman is told to download an app to record blood sugar. This app allows both patients and diabetologist to keep connected by exchanging text messages (short message service SMS) or progress reports via email [6].…”

Section: Discussionmentioning

confidence: 99%

Management of gestational diabetes during ‘COVID19 time’

Biase¹

2020

Ann Clin Endocrinol Metabol

View full text Add to dashboard Cite

The measures put in place by many governments around the world to fi ght the spread of COVID-19 have drastically reduced visits to diabetes centres. To keep providing people with diabetes the professional support they need and reduce the inconvenience caused by the interruption of traditional assistance, the typical control visit can be carried out by virtual visit, telemedicine (TM) that should have the necessary characteristics to provide a correct execution. Especially this is important for pregnant women fi rst diagnosed with gestational diabetes mellitus (GDM), they have the necessity to frequent checks in a short time due to the pregnancy.

show abstract

“…The other three systems showed slightly better accuracy results for study personnel measurements compared to lay-user measurements. Different studies showed that accuracy achieved by trained study personnel is often better than accuracy achieved by lay-persons [ 11 , 12 , 26 , 27 ]; however, only few user performance evaluations were performed on the basis of procedures described in ISO 15197:2013 [ 25 , 26 , 28 – 30 ].…”

Section: Discussionmentioning

confidence: 99%

User Performance Evaluation of Four Blood Glucose Monitoring Systems Applying ISO 15197:2013 Accuracy Criteria and Calculation of Insulin Dosing Errors

et al. 2018

View full text Add to dashboard Cite

IntroductionThe international standard ISO 15197:2013 requires a user performance evaluation to assess if intended users are able to obtain accurate blood glucose measurement results with a self-monitoring of blood glucose (SMBG) system. In this study, user performance was evaluated for four SMBG systems on the basis of ISO 15197:2013, and possibly related insulin dosing errors were calculated. Additionally, accuracy was assessed in the hands of study personnel.MethodsAccu-Chek® Performa Connect (A), Contour® plus ONE (B), FreeStyle Optium Neo (C), and OneTouch Select® Plus (D) were evaluated with one test strip lot. After familiarization with the systems, subjects collected a capillary blood sample and performed an SMBG measurement. Study personnel observed the subjects’ measurement technique. Then, study personnel performed SMBG measurements and comparison measurements. Number and percentage of SMBG measurements within ± 15 mg/dl and ± 15% of the comparison measurements at glucose concentrations < 100 and ≥ 100 mg/dl, respectively, were calculated. In addition, insulin dosing errors were modelled.ResultsIn the hands of lay-users three systems fulfilled ISO 15197:2013 accuracy criteria with the investigated test strip lot showing 96% (A), 100% (B), and 98% (C) of results within the defined limits. All systems fulfilled minimum accuracy criteria in the hands of study personnel [99% (A), 100% (B), 99.5% (C), 96% (D)]. Measurements with all four systems were within zones of the consensus error grid and surveillance error grid associated with no or minimal risk. Regarding calculated insulin dosing errors, all 99% ranges were between dosing errors of − 2.7 and + 1.4 units for measurements in the hands of lay-users and between − 2.5 and + 1.4 units for study personnel. Frequent lay-user errors were not checking the test strips’ expiry date and applying blood incorrectly.ConclusionsData obtained in this study show that not all available SMBG systems complied with ISO 15197:2013 accuracy criteria when measurements were performed by lay-users.Trial RegistrationThe study was registered at ClinicalTrials.gov (NCT02916576).FundingAscensia Diabetes Care Deutschland GmbH.Electronic supplementary materialThe online version of this article (10.1007/s13300-018-0392-6) contains supplementary material, which is available to authorized users.

show abstract

Evaluation of OneTouch Verio^®, a new blood glucose self-monitoring system for patients with diabetes

Abstract: The OneTouch Verio(®) displayed sufficient analytical quality and satisfactory user-friendliness. It is suitable for point-of-care testing of blood glucose concentration when handled by patients and healthcare professionals.

Cited by 11 publications

References 7 publications

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Management of gestational diabetes during ‘COVID19 time’

User Performance Evaluation of Four Blood Glucose Monitoring Systems Applying ISO 15197:2013 Accuracy Criteria and Calculation of Insulin Dosing Errors

Contact Info

Product

Resources

About

Evaluation of OneTouch Verio®, a new blood glucose self-monitoring system for patients with diabetes

Abstract: The OneTouch Verio(®) displayed sufficient analytical quality and satisfactory user-friendliness. It is suitable for point-of-care testing of blood glucose concentration when handled by patients and healthcare professionals.

Cited by 11 publications

References 7 publications

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study

Management of gestational diabetes during ‘COVID19 time’

User Performance Evaluation of Four Blood Glucose Monitoring Systems Applying ISO 15197:2013 Accuracy Criteria and Calculation of Insulin Dosing Errors

Contact Info

Product

Resources

About

Evaluation of OneTouch Verio^®, a new blood glucose self-monitoring system for patients with diabetes